Abstract: This invention relates to organometallic precursor compounds represented by the formula i-PrN?Ta(NR1R2)3 wherein R1 and R2 are the same or different and are alkyl having from 1 to 3 carbon atoms, provided that (i) when R1 is ethyl, then R2 is other than ethyl and (ii) when R2 is ethyl, then R1 is other than ethyl, and a method for producing a film, coating or powder from the organometallic precursor compounds.

Abstract: A method for the production of water-free rare earther metal halogenides by reacting rare earth metal oxides with a halogentation agent.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Abstract: The present invention provides 1) a complex comprising a mono-anionictridentate ligand, represented by the following general formula (I); 2) a polymerization catalyst composition, comprising the complex; and 3) a cis-1,4-isoprene polymer, a cis-1,4-butadiene polymer, a cis-1,4-isoprene-styrene copolymer, a cis-1,4-butadiene-styrene copolymer, a cis-1,4-butadiene-cis-1,4-isoprene copolymer, and a cis-1,4-butadiene-cis-1,4-isoprene-styrene copolymer, each of which has high-cis-1,4 content in a micro structure and a sharp molecular-weight distribution.

Abstract: This invention relates to porphyrin compounds used to destroy or impair the functioning of a target biological material in photodynamic therapy, in particular against virus, tumoral cells, bacteria, tumorous tissues. The invention also relates to compositions containing such compounds and to a method in vitro to photosensitize detroy or impair the functioning of such target biological material.

Abstract: Trimetallic nitride endohedral metallofullerene derivatives and their preparation are described. The trimetallic nitride endohedral metallofullerene derivatives have the general formula A3-nXn@Cm(R) where n ranges from 0 to 3, A and X may be trivalent metals and may be either rare earth metal or group IIIB metals, m is between about 60 and about 200, and R is preferably an organic group. Derivatives where the R group forms cyclized derivatives with the fullerene cage are also described.

Abstract: The invention relates to polyoxometalates represented by the formula (An)m+[R2(H2O)6X2W20O70]m? or solvates thereof, wherein A represents a cation, n is the number of the cations, m is the charge of the polyoxoanion, and X represents a heteroatom selected from SbIII, BiIII, AsIII, SeIV and TeIV, a process for their preparation and their use for the catalytic oxidation of organic molecules.

Abstract: Emulsions preferably of nanoparticles formed from high boiling liquid perfluorochemical substances, said particles coated with a lipid/surfactant coating are made specific to regions of activated endothelial cells by coupling said nanoparticles to a ligand specific for ?v?3 integrin, other than an antibody. The nanoparticles may further include biologically active agents, radionuclides, or other imaging agents.

Abstract: A pharmaceutical, wherein the formulation is a conjugate of a saccharide with one or a plurality of isotopic boron-10 atoms or gadolinium, and having a utility in the binary form of low energy neutron therapy (i.e. boron neutron capture therapy). Further, that the therapy has an indicated use for the selective targeting and killing of oxygenated and hypoxic cells in tumors, and that the pharmaceutical is preferentially taken up by cancer cells. The inclusion of any of a family of saccharides, its derivatives or analogues, including sulfur linkage saccharides as a delivery carrier for boron-10 atoms or the rare element gadolinium is a strategy to take advantage of the hallmark of cancer cells, that being an increased requisite for glucose to sustain a rate of uncontrollable cell division and proliferation. A cancer cell facilitates an increase in availability of molecular glucose by overexpression of glucose transporter proteins on membrane surfaces.

Abstract: The invention relates to compounds, to the complexes they form with a lanthanide, and to the use of the complexes for fluorescence marking or NMR imaging. The complex consists of an Ln ion and a ligand R2-C(X-R1)(R3)-NR4R5. R1 is a functional group, X is a single bond or a hydrocarbon-based chain consisting of at least one alkylene or alkenylene group optionally comprising at least one hetero atom or an arylene. R2 is an anionic group A2 or a C1-C4 alkylene or alkenylene group bearing at least one such group A2 and optionally comprising at least one hetero atom. R3 is H or a C1-C5 alkylene or alkenylene group optionally containing at least one hetero atom, and optionally bearing at least one anionic group A3. R4 is a substituent with light-absorbing properties that forms chelate rings with Ln. R5 is a substituent that forms chelate rings with Ln.

Abstract: A metalorganic complex composition comprising a metalorganic complex selected from the group consisting of: metalorganic complexes comprising one or more metal central atoms coordinated to one or more monodentate or multidentate organic ligands, and complexed with one or more complexing monodentate or multidentate ligands containing one or more atoms independently selected from the group consisting of atoms of the elements C, N, H, S, O and F; wherein when the number of metal atoms is one and concurrently the number of complexing monodentate or multidentate ligands is one, then the complexing monodentate or multidentate ligand of the metalorganic complex is selected from the group consisting of beta-ketoiminates, beta-diiminates, C2-C10 alkenyl, C2-C15 cycloalkenyl and C6-C10 aryl.

Abstract: The present invention relates to compounds and related technetium and rhenium complexes thereof which are suitable for imaging or therapeutic treatment of tumors, e.g., carcinomas, melanomas and other tumors. In another embodiment, the invention relates to methods of imaging tumors using radiolabeled metal complexes. Preferred radiolabeled complexes for imaging tumors include technetium and rhenium complexes. The high tumor uptake and significant tumor/nontumor ratios of the technetium complexes of the invention indicate that such small technetium-99m-based molecular probes can be developed as in-vivo diagnostic agents for melanoma and its metastases. In yet another embodiment, the invention relates to methods of treatment of tumors using a radiolabeled metal complex as a radiopharmaceutical agent to treat the tumor.

Abstract: Stable rare earth tris (organophosphate) solutions comprise a rare earth tris (organophosphate) and a hydrocarbon solvent. From about 2% to about 10% rare earth element, preferably from about 3% to about 8%, is present in the solutions. The rare earth tris (organophosphate) solutions are stable from precipitation of the rare earth tris (organophosphate) for at least about fifteen (15) days, preferably for at least about twenty (20) days and most preferably at least about thirty (30) days. A process for preparing these solutions is described herein. A stabilizing additive, acid, glycol or mixtures thereof, is utilized to inhibit precipitation. The molar ratios of free acid, glycol and/or water to the rare earth element are controlled to inhibit precipitation.

Abstract: The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium, in a fluorescence assay for an analyte using at least one fluorescent label, characterized in that a fluorescent conjugate comprising an oligonucleotide bonded to a rare-earth metal cryptate is introduced into the measuring medium.

Abstract: Disclosed are colorant compounds of the formulae wherein R1, R2, R3, M, A, E, G, J, m, n, and p are as defined herein.

Abstract: The present invention provides a process for preparing a melt-processed organic-inorganic hybrid material including the steps of maintaining a solid organic-inorganic hybrid material at a temperature above the melting point but below the decomposition temperature of the organic-inorganic hybrid material for a period of time sufficient to form a uniform melt and thereafter, cooling the uniform melt to an ambient temperature under conditions sufficient to produce the melt-processed organic-inorganic hybrid material.

Abstract: Disclosed are methods of using a transparent, luminescent polymer for transparent marking and/or labeling for identity verification purposes. Also disclosed are sheets, films, markers, labels and taggants comprising transparent, luminescent polymers. Also disclosed are articles labeled with a transparent, luminescent polymer. This invention particularly relates to use of transparent, luminescent polymer compositions comprising ethylene (meth)acrylic acid copolymers and rare earth ions and transparent, luminescent polymer compositions comprising methyl (meth)acrylate/(meth)acrylic acid copolymers, fatty acids and rare earth ions for these purposes.

Abstract: A compound for use as a photosensitiser in PDT, in photochemical internalisation in the production of a cancer vaccine or in the diagnosis or detection of medical conditions, the compound having a photosensitising chromophoric system, a sulphonamido functionality and a carboxy functionality. The compounds used in the present invention are photosensitisers in PDT in vivo, and show phototoxic activity in vitro. The compounds are used to treat pre-cancerous conditions, cancer, ophthalmological disease, vascular problems, arteriosclerosis and restenosis and autoimmune diseases, skin diseases and other benign conditions, and for anti-microbial treatments.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: A compound of formula I: wherein X1, X2, X3, X4, Y1, Y2, Y3, Y4 and Z have meanings given in the description, and metallated forms of such compounds, which are useful in the treatment of medical conditions for which a photodynamic compound is indicated. Pharmaceutical formulations and methods of treatment of a medical condition for which a photodynamic agent is indicated are also disclosed. Sterilizing solutions comprising a compound of the invention, and the use thereof, are also disclosed.

Abstract: New types of hydroxamic acid-based bifunctional chelators are provided. These chelators are designed to chelate metal ions that can be detected either by their paramagnetic or radioactive properties. Conjugation with peptides or protein can be achieved by the presence of a linker moiety in the molecular structure of these chelators.

Abstract: A new class of heterocyclic metallocenes, a catalytic system containing them and a process for polymerizing addition polymerizable monomers using said catalytic system are disclosed; the heterocyclic metallocenes correspond to the formula (I): YjR?iZjjMeQkPl wherein Y is a coordinating group containing a six ? electron central radical directly coordinating Me, to which are associated one or more radicals containing at least one non-carbon atom selected from B, N, O, Al, Si, P, S, Ga, Ge, As, Se, In, Sn, Sb and Te; R? is a divalent bridge between the Y and Z groups; Z is a coordinating group, optionally being equal to Y; Me is a transition metal; Q is halogen or hydrocarbon substituents; P is a counterion; i is 0 or 1; j is 1–3; jj is 0–2; k is 1–3; and l is 0–2.

Abstract: Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging.

Abstract: A method is described for the manufacture of hydrotalcites by using at least one compound of a bivalent metal (Component A) and at least one compound of a trivalent metal (Component B), wherein at least one of these components is not used in the form of a solution, characterized in that a) at least one of the Components A and/or B which is not used in the form of a solution, shortly before or during mixing of the components, and/or b) the mixture containing the Components A and B is subjected to intensive grinding until an average particle size (D50) in the range of approx. 0.1 to 5 ?m is obtained, and optionally, after aging treatment or hydrothermal treatment, the resulting hydrotalcite product is separated, dried, and optionally calcinated.

Abstract: The ability to design and construct solid-state materials with pre-determined structures is a grand challenge in chemistry. An inventive strategy based on reticulating metal ions and organic carboxylate links into extended networks has been advanced to a point that has allowed the design of porous structures in which pore size and functionality can be varied systematically. MOF-5, a prototype of a new class of porous materials and one that is constructed from octahedral Zn—O—C clusters and benzene links, was used to demonstrate that its 3-D porous system can be functionalized with the organic groups, —Br, —NH2, —OC3H7, —OC5H11, —H4C2, and —H4C4, and its pore size expanded with the long molecular struts biphenyl, tetrahydropyrene, pyrene, and terphenyl.

Abstract: A photo-functional molecule element having, on a substrate, a porphyrin polymer containing covalently-fixed porphyrin units, and the method of preparing the same. The photo-functional molecule element may be used as a photoelectric conversion element such as an organic solar cell or a three-dimensional, non-linear organic material.

Abstract: Compounds of general formula (I): in which: R1 is hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl, arylalkyl, or two R1, taken together, form a straight or cyclic C2–C10 alkylene group or an ortho disubstituted arylene; R2 is hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl or aryl alkyl optionally substituted with functional groups which allow conjugation with a suitable molecule able to interact with physiological systems; R3, R4 and R5 are hydrogen, C1–C20 alkyl, C3–C10 cycloalkyl, C4–C20 cycloalkylalkyl, aryl, arylalkyl; and their chelates with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203Pb 67Ga 68Ga 72As 111In 113In 90Y 97Ru 62Cu 64Cu 52Fe 52mMn 140La 175Yb 153Sm 166Ho 149Pm 177Lu 142Pr 159Gd 212Bi 47Sc 149Pm 67Cu, 111Ag, 199Au, 161Tb and 51Cr as well as the salts thereof with physiologically compatible bases or acids

Abstract: Novel coordination polymers, their pharmaceutical formulations, useful for treating atheroma, tumors and other neoplastic tissue, as well as other conditions that are responsive to the induction of targeted oxidative stress, are disclosed.

Abstract: The present invention provides an IR-absorbing dye of formula (I) or (II) wherein R10, R13, R20, R23, R30, R33, R40 and R43 are independently selected from a C1-12 alkyl group bearing a hydrophilic or hydrophilizable group; R11, R12, R21, R22, R31, R32, R41 and R42 are independently selected from H or a C1-30 hydrocarbyl group, or each of R11/R12, R21/R22, R31/R32, and R41/R42 are together joined to form a C3-30 hydrocarbylene group; M is selected from Si(A1)(A2), Ge(A1)(A2), Ga(A1), Mg, Al(A1), TiO, Ti(A1)(A2), ZrO, Zr(A1)(A2), VO, V(A1)(A2), Mn, Mn(A1), Fe, Fe(A1), Co, Ni, Cu, Zn, Sn, Sn(A1)(A2), Pb, Pb(A1)(A2), Pd and Pt; A1 and A2 are axial ligands, which may be the same or different, and are selected from —OH, halogen, —OR3, a hydrophilic ligand and/or a ligand suitable for reducing intermolecular interactions; R3 is a selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl or Si(Rx)(Ry)(Rz); and Rx, Ry and Rz may be the same or different and are selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl

Abstract: The present invention describes a novel group of specific transition metal compounds, referred to as nonmetallocene compounds, and catalyst systems prepared therefrom. These catalyst systems which have become obtainable for the first time are suitable for the polymerization of olefins.

Abstract: The present invention relates to improved diagnostic agents for Magnetic Resonance Imaging and optical imaging. In particular, this invention relates to MRI and optical imaging agents that allow for the sensitive detection of a specific bioactivity within a tissue. These agents are prodrug contrast agents which are bioactivated in vivo in the presence of the specific bioactivity. This invention also relates to pharmaceutical compositions comprising these agents and to methods of using the agents and compositions comprising the agents.

Abstract: A compound having the structural formula: where R is H or lower alkyl of 1 through 12 carbon atoms. In general, the compounds of the invention are 132-Oxo-bacteriopyropheophorbide—a carboxylic acid and C1–C12 alkyl esters thereof. A method for the preparation of the carboxylic acid compounds of the invention includes the step of reacting bacteriopyropheophorbide—a alkyl ester with lithium hydroxide tetrahydrofuran and water.

Abstract: The present invention provides an IR-absorbing naphthalocyanine dye of formula (I): wherein M is selected from Ga(A1); A1 is an axial ligand selected from —OH, halogen (preferably Cl), —OR3, a hydrophilic ligand and/or a ligand suitable for reducing cofacial interactions; R1 and R2 may be the same or different and are selected from hydrogen or C1-12 alkoxy (preferably C1-6 alkoxy); R3 is selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl or Si(Rx)(Ry)(Rz); and Rx, Ry and Rz may be the same or different and are selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl, C1-12 alkoxy, C5-12 aryloxy or C5-12 arylalkoxy; W is a hydrophilic group; n1 is 0, 1, 2 or 3; n2 is 0, 1, 2 or 3; n3 is 0, 1, 2 or 3; n4 is 0, 1, 2 or 3; provided that at least one of n1, n2, n3 or n4 is greater than 0. Dyes of this type are especially suitable for use in netpage and Hyperlabel™ systems.

Abstract: The organometallic compound of the present invention is a compound that has bonds between metal atoms and nitrogen atoms or bonds between semimetal atoms and nitrogen atoms, and the content of chlorine in the compound is 200 ppm or less and the content of water is 30 ppm or less. In addition, the general formula of this compound is represented by the following formula (1): M[(R1)2N](n?s)(R2)s??(1) wherein, M represents a metal atom or semimetal atom, with the metal atom being Hf, Zr, Ta, Ti, Ce, Al, V, La, Nb or Ni, and the semimetal atom being Si, R1 represents a methyl group or ethyl group, R2 represents an ethyl group, n represents the valence of M, and s represents an integer of 0 to n?1.

Abstract: The present invention provides an IR-absorbing dye of formula (I) or (II): wherein Q1, Q2, Q3 and Q4 are the same or different and are independently selected from a C3-20 heteroarylene group comprising at least one N atom; M is selected from Si(A1)(A2), Ge(A1)(A2), Ga(A1), Mg, Al(A1), TiO, Ti(A1)(A2), ZrO, Zr(A1)(A2), VO, V(A1)(A2), Mn, Mn(A1), Fe, Fe(A1), Co, Ni, Cu, Zn, Sn, Sn(A1)(A2), Pb, Pb(A1)(A2), Pd and Pt; A1 and A2 are axial ligands, which may be the same or different, and are selected from —OH, halogen, —OR3, a hydrophilic ligand and/or a ligand suitable for reducing cofacial interactions; R3 is a selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl or Si(Rx)(Ry)(Rz); and Rx, Ry and Rz may be the same or different and are selected from C1-12 alkyl, C5-12 aryl, C5-12 arylalkyl, C1-12 alkoxy, C5-12 aryloxy or C5-12 arylalkoxy. Dyes of this type are especially suitable for use in netpage and Hyperlabel systems.

Abstract: The invention provides methods and compositions for molecular resonance imaging of membrane potential. The compositions comprise an indicator moiety attached through an optional linker to a macrocycle component that binds a lanthanide. The indicator moiety changes conformation in response to alterations in membrane potential and alters the interaction of the bound lanthanide with water. This alteration produces a detectable change in MRI signal , notably the T1 value. A preferred indicator moiety is spiropyran as it exhibits membrane-potential driven interconversions between the closed-ring spiropyran conformer and the extended merocyanine conformer. A preferred macrocycle is DO3A, known to bind gadolinium and an established MRI contrast agent. The methods of the invention comprise in vivo and in vitro uses of compositions of the invention to obtain MRI images that provide information about membrane potential.

Abstract: A porphyrin metal complex that can form a stable oxygen complex and acts effectively as an oxygen infusion, which comprises: a transition metal ion M of period 4 or 5 coordinating to a porphyrin derivative represented by the following general wherein R1 is an alicyclic hydrocarbon group which may contain a substituent, R2 is an alkylene group and R3 is a group which does not hinder the coordination of an imidazolyl group to M.

Abstract: Lanthanum compounds are provided having general formulas (I) Rni+Yin? and (II) Rb+Yb? which may be used as medicaments in the prophylaxis and/or treatment of cancer diseases.

Abstract: The present invention provides an IR-absorbing naphthalocyanine dye of formula (I): wherein M is selected from Si(A1)(A2), Ge(A1)(A2), Ga(A1), Mg, Al(A1), TiO, Ti(A1)(A2), ZrO, Zr(A1)(A2), Vo, V(A1)(A2), Mn, Mn(A1), Fe, Fe(A1), Co, Ni, Cu, Zn, Sn, Sn(A1)(A2), Pb, Pb(A1)(A2), Pd and Pt; A1 and A2 are axial ligands, which may be the same or different, and are selected from —OH, halogen, —OR3, a hydrophilic ligand and/or a ligand suitable for reducing cofacial interactions; R1 and R2 are selected from H or C1-12alkoxy; R3 is selected from C1-12alkyl, C5-12aryl, C5-12arylalkyl or Si(Rx)(Ry)(Rz); and Rx, Ry and Rz may be the same or different and are selected from C1-12alkyl, C5-12aryl, C5-12arylalkyl, C1-12 alkoxy, C5-12aryloxy or C5-12arylalkoxy; W is a hydrophilic group; n1 is 0, 1, 2 or 3; n2 is 0, 1, 2 or 3; n3 is 0, 1, 2 or 3; n4 is 0, 1, 2 or 3; provided that at least one of n1, n2, n3 or n4 is greater than 0. Dyes of this type are especially suitable for use in netpage and Hyperlabel systems.

Abstract: The present invention provides certain non-symmetric tripyrranes; that is, tripyrranes that do not contain a mirror plane of symmetry perpendicular to the plane containing the tripyrrane. Further, the invention includes texaphyrin compounds and sapphyrin compounds, as well as other polypyrrolic macrocycles, prepared using tripyrranes of Formula I as a precursor. These macrocycles are characterized by a tripyrrolic portion of the macrocyclic ring having substituents that cause the heterocycle to lack a plane of symmetry perpendicular to the plane of the macrocycle.

Abstract: The present invention provides a composition and process using the composition for removing metal ions from aqueous process solutions. These compositions include a non-metallic compound and a suitable carrier. In one embodiment, the non-metallic compound is a thiuram. In another embodiment, the non-metallic compound can further include a dithiocarbamate. These compositions are contacted with the metal ions in the aqueous process solution having a wetting agent to form an organometallic complex precipitate. The precipitate can then be separated from the aqueous solution.

Abstract: The present invention provides a process for preparing a melt-processed organic-inorganic hybrid material including the steps of maintaining an solid organic-inorganic hybrid material at a temperature above the melting point but below the decomposition temperature of the organic-inorganic hybrid material for a period of time sufficient to form a uniform melt and thereafter, cooling the uniform melt to an ambient temperature under conditions sufficient to produce the melt-processed organic-inorganic hybrid material.

Abstract: A subject of the present invention is new compounds having a lanthanide and having a tridentate ligand, a process for their preparation and their use in particular as polymerization catalysts.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

Abstract: A covalently linked linear porphyrin polymer represented by formula (1): wherein R represents an alkyl group or ?(wherein a, b and d independently represent H, an alkyl group or aryl group); X represents —O—, —S—, >NR101 (wherein R101 represents H or an alkyl group), —CH2— or a single bond; Y represents ?O, ?S, or 2H; m represents an integer of 0 to 4; n represents an integer of 0 to 6; Z represents a five- or six-membered, nitrogen-containing, coordinating hetero aromatic ring group; M represents an ion of metal selected from typical metals and transition metals; Q1 represents a single bond or a linear, divalent linking group; and p1 represents an integer of 2 or more.

Abstract: An organic electroluminescence device comprises a cathode, an anode and a layer of an organic thin film comprising one or a plurality of layers and disposed between the cathode and the anode, wherein at least one of the layers in the layer of an organic thin film comprises a laminate of a layer comprising a metal complex having an energy gap of 2.8 eV or greater and a layer of a host material. The organic electroluminescence device exhibits a higher efficiency of light emission and has a longer life than conventional devices while the emitted light has a high luminance.

Abstract: The invention relates to novel, water-soluble porphyrin platinum compounds of the tetraarylporphyrin platinum derivatives type or of the hematoporphyrin platinum derivatives type with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases. In particular, the compounds are suitable for photodynamic anti-tumor therapy.

Abstract: The invention relates to a process for reducing the fluorescence quenching caused by the measuring medium in a fluorescence assay, by introducing into said medium of rare earth metal cryptates which are not very sensitive to this fluorescence quenching, said rare earth metal cryptates comprising at least one pyridine radical which is substituted one or more times or unsubstituted. The invention also relates to novel rare earth metal cryptates which are not very sensitive to the fluorescence quenching caused by the measuring medium.

Abstract: The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.